β_1肾上腺素能受体Gly389Arg多态性与原发性高血压的关系

目的探讨汉族人群β1肾上腺素能受体Gly389Arg多态性与原发性高血压的关系。方法采用聚合酶链反应-限制性长度片段多态性技术分析原发性高血压患者和正常人群β1肾上腺素能受体Gly389Arg多态性。结果高血压组Arg/Arg,Arg/Gly,Gly/Gly基因型频率分别为59.06%、35.09%、5.85%,正常对照组分别为43.55%、45.97%、10.48%;两组间三种基因型频率分布有统计学差异(χ2=7.420,P<0.05);高血压组Arg等位基因频率为76.61%,Gly等位基因频率为23.39%,正常对照组分别为66.53%、33.47%,两组间等位基因频率分布存在统计学差异(χ2=7.299,P<0.05);高血压组Arg纯合子基因型频率和Arg等位基因频率均明显高于对照组。结论β1肾上腺素能受体Gly389Arg多态性可能与原发性高血压发病有关。     

β1肾上腺素能受体Ser49Gly多态性与原发性高血压的关系

目的探讨汉族人群β1肾上腺素能受体多态性与原发性高血压的关系。方法采用聚合酶链反应-限制酶片段长度多态性（PCR-SLFP）技术分析高血压病患者和正常对照组β1肾上腺素能受体（β1-AR）Ser49Gly多态性。结果高血压组Set49等位基因频率为86．6％，Gly49等位基因频率为13．4％，对照组分别为89．7％和10．3％，两组等位基因频率分布比较无统计学差异（P〉0．05）；高血压组Ser／Ser基因型占64．3％，Ser／Gly基因型占26．7％，Gly／Gly基因型占0％，对照组分别为80．1％、19．2％和0．6％，两组基因型频率分布比较无统计学差异（P〉0．05）。结论β1-AR Ser49Gly多态性可能与本研究群体的高血压病无关。     

β2肾上腺素受体Arg16Gly基因多态性与原发性高血压的相关性研究

目的:研究河北地区汉族人β2肾上腺素受体(β2-Adrenergic Receptor, β2-AR)Arg16Gly基因多态性与原发性高血压(EH)的关系.方法:选择514例EH患者及550例正常人,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析β2-AR Arg16Gly基因型.结果:EH组β2-AR Arg16Arg,Arg16Gly,Gly16Gly基因型频率分别为21.3%、54.8%和23.9%,正常对照组分别为28.2%、68.2%和3.6%,2组间3种基因型频率差异有统计学意义(P<0.05).EH组β2-AR Arg16等位基因频率为51.8%,Gly16等位基因频率为48.2%;正常对照组分别为63.9%和36.1%,2组间等位基因频率比较,差异有统计学意义(P<0.05).结论:β2-AR Arg16Gly多态性Gly等位基因可能是EH的遗传易感基因.     

β1肾上腺素能受体基因多态性与心血管疾病

β1肾上腺素能受体是在心肌细胞分布的主要β肾上腺素能受体亚型,在调节心率和心肌收缩力方面起主导作用。随着β1肾上腺素能受体基因两个单核苷酸多态性(singlenuclid polymorphism,SNP)的发现,β1肾上腺素能受体基因可能成为某些心血管疾病病因研究的候选基因,并可能与     

β1肾上腺能受体基因Ser49Gly多态性与原发性高血压相关性研究

目的　探讨 β1肾上腺能受体 (以下简称 β1受体 )基因Ser49Gly多态性在原发性高血压 (essentialhypertension ,EH)发病机制中的作用。方法　选择 80例EH患者及 85例正常对照者 ,应用聚合酶链反应 -限制性片段长度多态性( polymerasechainreaction restrictionfragmentlengthpolymorphism ,PCR RFLP)技术分析基因多态性。 结果　EH组和对照组的Ser/Ser、Ser/Gly和Gly/Gly基因型频率分别为 :0 79、0 2 1、0和 0 80、0 19、0 0 1(P >0 5)。Ser和Gly的等位基因频率在高血压组和对照组均分别为 0 89和 0 11,两组间无差异 (P >0 5)。这两组的Ser/Gly多态性分布均符合Hardy Weinberg定律。结论　在所研究的中国人群中 ,β1受体基因Ser49Gly多态性与原发性高血压的发病无联系     

β2肾上腺素能受体基因多态性与原发性高血压的相关性研究

目的:检测贵州汉族人群β2 肾上腺素能受体基因Gln27Glu多态性,并探讨其与贵州汉族人群原发性高血压(EH)以及其他心血管病危险因素的关系。方法:选择131例EH患者及40例正常人为对象,通过聚合酶链反应确定基因型,并测定每个对象的体质指数(BMI)、腰围、臀围、腰围/臀围、空腹血三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL- C)、高密度脂蛋白胆固醇(HDL- C)以及LP(α)等。结果:①Gln27Glu多态性的基因型频率和等位基因频率在EH组和对照组间差异无统计学意义 (P>0.05),但 Glu27/Glu、Gln27/Glu基因型频率和Glu27等位基因频率在3级EH组的比例明显高于其在对照组及 1、2 级 EH组的比例(P<0.05);②Glu27/Glu、Gln27/Glu两种基因型个体的TC显著高于 Gln27/Gln基因型个体 (P<0.05),而 BMI、腰围/臀围、TG、LDL- C、HDL- C以及LP(α)等在三种基因型之间差异无统计学意义(P>0.05)。结论:Gln27Glu基因多态性与3级EH及TC有关联。     

β3肾上腺素能受体基因多态性与原发性高血压相关性研究现状

原发性高血压(EH)常伴随着代谢方面的异常,如肥胖、体重增加、胰岛素抵抗(IR)、糖尿病(DM)等,这些均被证实与β3肾上腺素能受体(β3-AR)基因的多态性有关。β3-AR是交感神经系统的重要组成部分,它主要介导脂肪分解与热生成作用,该受体激动时局部脂肪分解增加。如果决定β3-AR性     

β2-肾上腺素能受体多态性与高血压

高血压是一复杂疾病,环境和基因因素决定其最终的表型.大量研究提示,高血压患者体内存在β2-肾上腺素能受体(β2-AR)调节的改变,这些变动可能与β2-AR编码区单核苷酸改变有关,其中16、27位点基因的改变很常见.本文对β2-AR多态性参与高血压发病的病理生理学机制进行探讨.     

β1肾上腺能受体基因Ser49Gly多态性与原发性高血压相关性研究

目的探讨β1肾上腺能受体(以下简称β1受体)基因Ser49Gly多态性在原发性高血压(essential hypertension, EH)发病机制中的作用.方法选择80例EH患者及85例正常对照者,应用聚合酶链反应-限制性片段长度多态性(polymerase chain reaction-restriction fragment length polymorphism, PCR-RFLP)技术分析基因多态性.结果 EH组和对照组的Ser/Ser、Ser/Gly 和Gly/Gly 基因型频率分别为 0.79、0.21、0和0.80、0.19、0.01(P>0.5).Ser和Gly的等位基因频率在高血压组和对照组均分别为0.89和0.11,两组间无差异(P>0.5).这两组的Ser/Gly多态性分布均符合Hardy-Weinberg定律.结论在所研究的中国人群中,β1受体基因Ser49Gly多态性与原发性高血压的发病无联系.     

中国北方汉族人群β3-肾上腺素能受体基因Trp64Arg多态性与原发性高血压的相关性研究

目的:探讨我国北方汉族人群β3-肾上腺素能受体基因单核苷酸多态性位点Trp64Arg与原发性高血压的相关性。方法:入选在北京安贞医院就诊的北方汉族原发性高血压患者855例(原发性高血压组,HT组),以及同期在安贞医院健康体检中心体检血压正常的受试者665例(正常血压对照组,NT组)。运用TaqMan等位基因分型技术,采用ABI7900基因检测平台对受试者ADRB3基因Trp64Arg位点进行检测,评估该多态性位点与我国北方汉族人群原发性高血压发病风险的关系。结果:HT组和NT组的ADRB3基因Trp64Arg位点基因型频率间,差异有统计学意义(P=0.017)。其中,ArgArg、ArgTrp及TrpTrp基因型在HT组和NT组的分布频率分别为1.29%/2.87%、30.25%/25.53%及68.46%/71.69%。多因素Logistic回归分析结果显示,除显性模型和等位基因模型外(显性模型:OR=1.233,95%CI=0.916～1.659,P=0.168;等位基因模型:OR=1.073,95%CI=0.828～1.390,P=0.595),各遗传模型均显示该多态性与原发性高血压发病密切相关(隐形模型:OR=0.343,95%CI=0.138～0.850,P=0.021;纯合子模型:OR=0.368,95%CI=0.147～0.921,P=0.033;加性模型:OR=0.374,95%CI=0.150～0.932,P=0.035;超显性模型:OR=1.412,95%CI=1.038～1.920,P=0.028)。根据性别进行的亚组分析中,仅在女性人群中发现该相关性(P=0.026)。根据超体质量/肥胖与否以及性别联合是否超体质量/肥胖进行的分层分析中,均未发现该相关性。结论:在本研究人群中,β3肾上腺素能受体基因Trp64Arg多态性可能与原发性高血压相关,Arg64Arg纯合子可能会降低高血压发病风险,杂合子Arg64Trp可能是高血压发病的危险因素。     

The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis.

BACKGROUND: The beta1-adrenoceptor is a candidate gene for obesity because of its role in catecholamine-induced energy homeostasis. A common Arg 389 Gly variant polymorphism has been shown in recombinant cells to influence its-coupling properties. OBJECTIVE: To investigate the effect of the Arg 389 Gly beta1-adrenoceptor polymorphism on catecholamine-induced lipolysis in native human fat cells obtained by subcutaneous biopsy. SUBJECTS: Two-hundred and ninety-eight apparently healthy male and female subjects with a wide variation in body mass index (BMI, 18-60 kg/m2). MEASURES: The lipolytic sensitivities and maximum lipolytic action of noradrenaline and the selective adrenoceptor agonists dobutamine (beta1), terbutaline (beta2) and CGP 12177 (beta3) were determined in isolated subcutaneous adipocytes and related to beta-adrenoceptor radioligand binding parameters. RESULTS: No differences in the sensitivity or maximum lipolytic capacity of the agonists were found between the genotypes. This was true both when all subjects were analyzed together and when subgroups (lean, obese, men, women) were analyzed separately. Radioligand binding to beta1- or beta2-adrenoceptors was also similar between genotypes. The polymorphism had no important influence on either BMI or the distribution of obese and non-obese subjects between the genotypes. CONCLUSION: The distribution of the Arg 389 Gly polymorphism is similar in lean and obese subjects and has no apparent effect on the lipolytic response to beta-adrenergic stimulation in native human adipocytes. This suggests, despite the altered coupling properties reported in recombinant cells, that the Arg 386 Gly polymorphism has no important influence on human obesity.     

Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction

Background

We sought to investigate the relation between the Arg389Gly polymorphism in the human β1-adrenergic receptor (ADRB1) gene and acute myocardial infarction (AMI). It was previously reported that augmented sympathetic activity might play an important role as a trigger of AMI by enhanced hemodynamic or mechanical forces through ADRB1 activation. Recently, a common polymorphism has been identified at amino acid position 389 (Arg or Gly) of the human ADRB1, within a region important for receptor-Gs protein coupling and subsequent agonist-stimulated adenylyl cyclase activation.

Methods

To investigate the relation between the Arg389Gly polymorphism in the ADRB1 gene and AMI, we genotyped 354 patients with AMI and 354 age- and sex-matched control subjects by use of polymerase chain reaction amplification and the restriction fragment length polymorphism analysis.

Results

The prevalence of the Arg389 homozygote (CC) genotype was significantly more frequent in patients with AMI than in control subjects (68.1% vs 47.2%, P < .0001). In logistic regression models, the odds ratio (OR) of Arg389 homozygote (CC) versus Arg389Gly heterozygote (CG) + Gly389 homozygote (GG) genotypes between control subjects and patients with AMI was 2.86 (95% CI 1.92-4.26, P = .0001). The association of the Arg389Gly polymorphism of ADRB1 with AMI was statistically significant and independent of other risk factors.

Conclusion

Our findings suggest that the genotype of Arg389Gly polymorphism in the human ADRB1 gene is associated with AMI.     

The Arg389Gly beta1-adrenergic receptor gene polymorphism and susceptibility to faint during head-up tilt test.

AIMS: To investigate the association of the Gly389 allele with positive head-up tilt test (HUT) in a Mexican Mestizo population. METHODS AND RESULTS: HUT results were compared between carriers (one or two copies of the Gly389 allele) and non-carriers (Arg389Arg genotype) of the Gly389 allele of the beta(1)AR gene in 50 patients with unexplained syncope. Thirty-three patients (66%) had a positive HUT. Patients with a positive HUT had a higher Gly389 allele frequency compared with those with a negative test (30.3 vs. 3%; OR 13; pC = 0.012). Moreover, when comparing positive HUT in passive drug-free phase, positive HUT in pharmacological (nitrate) phase, and negative (both phases), a decreasing gradient in the frequencies of the Gly389 allele was found among the three groups: 45.4, 22.7, and 3%, respectively. CONCLUSION: An association of positive tilt table testing to a single nucleotide polymorphism with a Gly to Arg switch at position 389 of the beta(1)AR was found. This polymorphism may contribute to susceptibility to faint during orthostatic challenge.     

Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension

BACKGROUND: Studies suggest that the Ser49Gly and Arg389Gly polymorphisms in the beta1-adrenergic receptor might be of functional importance for the cardiovascular system. Both have been associated with altered receptor activity in vitro, and with hypertension and cardiac failure in vivo. HYPOTHESIS: The aim of this study was to test whether these polymorphisms were associated with the change in heart rate or blood pressure in patients with essential hypertension and left ventricular (LV) hypertrophy treated with the beta1-adrenergic receptor blocker atenolol. METHODS: Blood pressure and heart rate were measured in 101 hypertensive patients with echocardiographically verified LV hypertrophy, randomized in a double-blind study to treatment with either the beta1-adrenergic receptor blocker atenolol or the angiotensin II type I receptor antagonist irbesartan. Changes in blood pressure and heart rate were evaluated after 12 weeks. Beta1-adrenergic receptor genotyping was performed using polymerase chain reaction and restriction fragment length polymorphism. RESULTS: We found no significant associations between the changes in the measured variables and either of the two polymorphisms. However, carriers of the 49Gly allele showed a tendency toward a greater reduction in heart rate compared with patients with the Ser/Ser49 genotype (p = 0.06). CONCLUSIONS: The Ser49Gly and Arg389Gly beta1-adrenergic receptor polymorphisms do not seem to exert a major effect on the changes in heart rate and blood pressure during 12 weeks of treatment with atenolol in patients with essential hypertension and LV hypertrophy.     

Studies of associations between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects.

AIMS: Activation of the beta(1)-adrenergic receptor (ADRB1) causes increased lipolysis in adipose tissue and enhances cardiac output. Analysis of the association of the functional ADRB1 Arg389Gly variant with obesity and hypertension has given ambiguous results. To clarify the potential impact of this variant on obesity and hypertension in the general population, we examined the Arg389Gly variant in a relatively large-scale population-based study. METHODS: Case-control studies and quantitative trait analyses were carried out in 7677 Danish Caucasians who were genotyped for the Arg389Gly variant (dbSNP rs1801253) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. RESULTS: A weak association between the Gly allele of the Arg389Gly variant and obesity was observed when comparing cases (n = 1540) defined as body mass index (BMI) > 30 kg/m(2) with control subjects (n = 6108) defined as BMI < or = 30 kg/m(2) for both allele frequencies (P = 0.05) and genotype distribution (P = 0.05). Case-control studies (cases n = 2518; control n = 3981) examining the effect on hypertension showed no association with allele frequencies (P = 0.3) or genotype distribution (P = 0.5); however, in the quantitative trait analyses, individuals carrying the Gly allele had slightly but significantly lower diastolic (Arg/Arg = 81.9 mmHg vs. Gly-allele carriers = 81.5 mmHg) and systolic (Arg/Arg = 129.4 mmHg vs. Gly-allele carriers = 128.8 mmHg) blood pressure as well as a lower mean arterial blood pressure. CONCLUSION: Our results suggest that the Arg389Gly polymorphism does not have any clinically important impact on the pathogenesis of obesity in Danish white subjects. Furthermore, despite the observed minor influence on blood pressure, this variant is most likely not to be a major contributor to the development of hypertension.     

Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49Gly and Gly389Arg beta(1)-adrenergic receptor polymorphisms in human right atrium in vitro

OBJECTIVE: The goal of this study was to determine whether the cardiostimulant effects of the endogenous beta(1)-adrenergic receptor (AR) agonist, (-)-norepinephrine are modified by polymorphic (Serine49Glycine [Ser49Gly], Glycine389Arginine [Gly389Arg]) variants of beta(1)-ARs in the nonfailing adult human heart. BACKGROUND: Human heart beta(1)-ARs perform a crucial role in mediating the cardiostimulant effects of (-)-norepinephrine. An understanding of the significance of Ser49Gly and Gly389Arg polymorphisms in the human heart is beginning to emerge, but not as yet in adult patients who have coronary artery disease (CAD). METHODS: The potency and maximal effects of (-)-norepinephrine at beta(1)-ARs (in the presence of beta(2)-AR blockade with 50 nM ICI 118,551 [erythro-DL-1(7-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol]) for changes in contractile force and shortening of contractile cycle duration were determined in human right atrium in vitro from 87 patients undergoing coronary artery bypass grafting who were taking beta-blockers before surgery. A smaller sample of patients (n = 20) not taking beta-blockers was also investigated. Genotyping for two beta(1)-AR polymorphisms (Ser49Gly and Gly389Arg) was determined from a sample of blood taken at the time of surgery. RESULTS: (-)-Norepinephrine caused concentration-dependent increases in contractile force and reductions in time to reach peak force and time to reach 50% relaxation. There were no differences in the potency or maximal effects of (-)-norepinephrine in the right atrium from patients with different Ser49Gly and Gly389Arg polymorphisms. CONCLUSIONS: The cardiostimulant effects of (-)-norepinephrine at beta(1)-ARs were conserved across Ser49Gly and Gly389Arg polymorphisms in the right atrium of nonfailing hearts from patients with CAD managed with or without beta-blockers.     

Association between nonspecific airway hyperresponsiveness and Arg16Gly beta2-adrenergic receptor gene polymorphism in asymptomatic healthy Japanese subjects

BACKGROUND: Nonspecific airway hyperresponsiveness (AHR), a cardinal feature of asthma, is thought to result from several genetic and environmental factors. Asymptomatic AHR in nonasthmatic healthy subjects might be a risk factor for the development of asthma. Genetic variations in codons 16 and 27 of the human beta(2)-adrenergic receptor (beta(2)-AR) alter receptor function in vitro and are associated with various asthma-related phenotypes, including asthma severity and AHR. To date, however, few reports have examined the impact of beta(2)-AR gene polymorphism on AHR in asymptomatic healthy subjects. OBJECTIVE: To determine whether polymorphism of the beta(2)-AR gene (Arg16Gly and Gln27Glu) might influence nonspecific AHR in asymptomatic healthy Japanese subjects. DESIGN AND PARTICIPANTS: A cohort of 120 asymptomatic healthy subjects was analyzed using a stepwise linear regression model. Nonspecific airway responsiveness was measured using a continuous methacholine inhalation method (Astograph; Chest; Tokyo, Japan). We used values of the cumulative dose of inhaled methacholine measured at the inflection point at which respiratory conductance starts to decrease (Dmin) as an index of AHR. Genotyping to identify polymorphisms at codons 16 and 27 was conducted using an assay combining kinetic real-time quantitative polymerase chain reaction with allele-specific amplification. RESULTS: The Gly16Gly genotype was associated with lower Dmin values. The log Dmin value of asymptomatic healthy subjects carrying the Arg16 allele (Arg16/Arg or Arg16/Gly, n = 90) was 1.09 +/- 0.56 (mean +/- SD), while those homozygous for the Gly16 allele (n = 30) yielded a log Dmin value of 0.85 +/- 0.56 (p < 0.05). CONCLUSION: This study indicates that a specific beta(2)-AR polymorphism at codon 16 might be a genetic determinant of AHR, as judged by methacholine-induced bronchoconstriction in asymptomatic healthy subjects.     

β2-肾上腺素能受体多态性/单倍型与支气管哮喘表型的相关性

目的 研究β2-肾上腺素能受体基因的多态性/单倍型与支气管舒张剂的反应性及血清免疫球蛋白E的负对数(lgIgE)间的关系.方法 2006年2月至2007年2月采用DNA测序法测定了201例哮喘患者(哮喘组)和276名健康对照者(健康对照组)的β2-AR基因5个位点(-47、-20、46、79、252)的基因型并确定其单倍型.统计学处理采用SPSS 11.5软件.以拟和优度的x2检验计算各位点基因型频率是否符合Hardy-Weinberg平衡.5个位点基因型的频率比较采用卡方检验,位点间的连锁不平衡采用确切概率法,不同基因型及单倍型与定量指标间的比较采用方差分析.如果方差分析有统计学意义,则用LSD方法对各组间的值进行两两比较.结果 哮喘组中Arg16Arg16基因型患者的支气管舒张剂反应性为(13±4)L,与Arg16Gly16基因型[(7±3)L]及G1y16Gly16基因型[(7±3)L]比较差异有统计学意义(F=81.55,P＜0.01);在哮喘组6种单倍型中,单倍型Arg16Gln27/Arg16Gln27的△FEV1最高[(13.4±3.5)L],与其他种单倍型[Gly16Gln27/Gly16Gln27(6.4±0.6)L、Gly16Glu27/Gly16Glu27(7.6±3.1)L、Gly16Gln27/Gly16Glu27(6.9±3.5)L、Gly16Gln27/Arg16Gln27(7.2±3.3)L及Gly16Glu27/Arg16Gln27(7.9±2.7)L]比较差异有统计学意义(F=32.55,P＜0.01);哮喘组中Gln27Gln27基因型患者的血清lgIgE为(2.51±0.33)IU/L,与Gln27Glu27基因型患者的血清lgIgE[(2.30±0.82)IU/L]比较差异有统计学意义(F=3.89,P＜0.05);哮喘组中单倍型Gly16Glu27/Arg16Gln27的血清lglgE最低[(2.13±0.15)IU/L],与其他4种单倍型[Arg16Gln27/Arg16Gln27为(2.56±0.14)IU/L、Gly16Glu27/Gly16Glu27为(2.40±0.16)IU/L、Gly16Gln27/Gly16Glu27为(2.54±1.26)IU/L、Gly16Gln27/Arg16Gln27为(2.48±0.48)IU/L]比较差异有统计学意义(F=3.56,P＜0.01).结论 依据所研究的哮喘表型,无论是β2-AR基因的多态性,还是单倍型均可能影响疾病的表现.